Annals of Oncology
IF
18.27
Papers
35899
Papers 10000
1 page of 1,000 pages (10k results)
Newest
#1Carsten Denkert (Charité)H-Index: 82
#2Michael UntchH-Index: 76
Last. S. Loibl (Goethe University Frankfurt)H-Index: 34
view all 28 authors...
BACKGROUND Different endogenous and exogenous mutational processes act over the evolutionary history of a malignant tumor, driven by abnormal DNA editing, mutagens or age-related DNA alterations, among others, to generate the specific mutational landscape of each individual tumor. The signatures of these mutational processes can be identified in large genomic datasets. We investigated the hypothesis that genomic patterns of mutational signatures are associated with the clinical behavior of breas...
Source
#1M. Martin (Complutense University of Madrid)H-Index: 5
#1M. Martin (Complutense University of Madrid)H-Index: 16
Last. Miguel Gil-GilH-Index: 12
view all 33 authors...
Abstract Background Palbociclib plus endocrine therapy (ET) is the standard treatment for hormone receptor-positive and human epidermal growth factor receptor 2-negative, metastatic breast cancer (MBC). However, its efficacy has not been compared with that of chemotherapy in a phase III trial. Patients and Methods PEARL is a multicentre, phase III randomised study in which patients with aromatase inhibitors (AIs)-resistant MBC were included in two consecutive cohorts. In cohort 1 (C1), patients ...
3 CitationsSource
#1Paolo Bossi (University of Brescia)H-Index: 33
#2A. T. Chan (CUHK: The Chinese University of Hong Kong)H-Index: 6
Last. Euracan
view all 14 authors...
Source
#1Ho-Young YhimH-Index: 12
#2T. Kim (Chonnam National University)
Last. Deok-Hwan Yang (Chonnam National University)H-Index: 21
view all 11 authors...
Background Current treatment options for peripheral T-cell lymphomas (PTCLs) in the relapsed/refractory setting are limited and demonstrate modest response rates with rare achievement of complete response (CR). Patients and methods This phase 1/2 study (NCT03052933) investigated the safety and efficacy of copanlisib, a phosphatidylinositol 3-kinase (PI3K)-α/-δ inhibitor, in combination with gemcitabine in 28 patients with relapsed/refractory PTCL. Patients received escalating doses of intravenou...
Source
#1Y. Shi (Peking Union Medical College)
#1Yuankai Shi (Peking Union Medical College)H-Index: 31
Last. Yufen Zhao (Zhengzhou University)H-Index: 58
view all 20 authors...
Source
#1Y. Di Filippo (French Institute of Health and Medical Research)
#2Stéphane DalleH-Index: 45
Last. Henri Montaudié (French Institute of Health and Medical Research)H-Index: 14
view all 26 authors...
Background The “obesity paradox” suggests that higher body mass index (BMI) is associated with better survival values in metastatic melanoma patients, especially those receiving targeted and immune checkpoint inhibitor therapy. Higher BMI is also associated with higher incidences of treatment-related adverse events. This study assesses whether body mass index is associated with survival outcomes and adverse events in metastatic melanoma patients with systemic therapy. Patients and methods This m...
Source
#1E. Ococks (University of Cambridge)H-Index: 2
#2Alexander M. Frankell (University of Cambridge)H-Index: 1
Last. Elizabeth C. Smyth (Cambridge University Hospitals NHS Foundation Trust)H-Index: 5
view all 15 authors...
BACKGROUND The incidence of esophageal adenocarcinoma (EAC) is rapidly rising and has a 5-year survival rate <20%. Beyond TNM staging, no reliable risk stratification tools exist and no large-scale studies have profiled ctDNA at relapse in EAC. Here we analyze the prognostic potential of ctDNA dynamics in EAC, taking into account clonal hematopoiesis with indeterminate potential (CHIP). PATIENTS AND METHODS 245 samples from 97 patients treated with neoadjuvant chemotherapy and surgery were ident...
1 CitationsSource
#1Thomas BachelotH-Index: 31
#2Florence DalencH-Index: 22
Last. Fabrice Andre (Institut Gustave Roussy)H-Index: 90
view all 20 authors...
Source
Source
#1A.B. Carpenter (Georgetown University)
#2A.M. Carpenter (RU: Rutgers University)
Last. S. Hanft (NYMC: New York Medical College)
view all 4 authors...
Gliomas remain one of the more frustrating targets for oncologic therapy. Glioma resistance to conventional therapeutics is a product of their immune-privileged milieu behind the blood-brain barrier, in addition to their suppressive effect on the immune response itself. Taking the lead from the growing success of immunotherapy for systemic cancers such as lung cancer and melanoma, immunotherapeutics has emerged as a major player in the potential treatment of gliomas, with oncolytic viruses in pa...
Source
12345678910
Top fields of study
Cancer
Pathology
Oncology
Chemotherapy
Breast cancer
General surgery
Medicine